Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 7/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5593284 | 0.84 | OPRK1 (0.51) | OPRK1CYP2C19MAPTALDH1A1CYP1A2 | |
| SCHEMBL30618280 | 0.83 | OPRK1 (0.50) | OPRK1CYP2C19MAPTALDH1A1CYP1A2 | |
| SCHEMBL8326765 | 0.83 | OPRK1 (0.50) | OPRK1CYP2C19MAPTALDH1A1CYP1A2 | |
| SCHEMBL31426614 | 0.83 | OPRK1 (0.50) | OPRK1CYP2C19MAPTALDH1A1CYP1A2 | |
| SCHEMBL1680354 | 0.83 | OPRK1 (0.50) | OPRK1CYP2C19MAPTALDH1A1CYP1A2 | |
| SCHEMBL2692671 | 0.83 | OPRK1 (0.50) | OPRK1CYP2C19MAPTALDH1A1CYP1A2 | |
| SCHEMBL31433790 | 0.82 | OPRK1 (0.49) | OPRK1CYP2C19MAPTALDH1A1KMT2A | |
| SCHEMBL1818933 | 0.80 | MAPT (0.49) | MAPTALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL28787258 | 0.80 | MAPT (0.50) | OPRK1CYP2C19MAPTALDH1A1GAA | |
| SCHEMBL28403320 | 0.80 | OPRK1 (0.47) | OPRK1CYP2C19MAPTALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-108929263-B | Arylamide Kv2.1 inhibitor and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2022-07-22 | — | — | CN | disclosed |
| CN-111108092-A | Arylamide Kv2.1 inhibitor and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2020-05-05 | — | — | CN | disclosed |
| CN-108929263-A | Aryl amide Kv2.1 inhibitor and preparation method thereof, pharmaceutical composition and purposes | 中国医学科学院药物研究所 | 2018-12-04 | — | — | CN | disclosed |
| US-9873693-B2 | Methods of treatment using pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-8778977-B2 | Pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778977-B2 | Pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20100144730-A1 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHAMACEUTICALS (US) | 2010-06-10 | — | — | US | disclosed |
| US-20090048286-A1 | Inhibitors of Protein Tyrosine Phosphatase 1B | WYETH (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048286-A1 | Inhibitors of Protein Tyrosine Phosphatase 1B | WYETH (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048286-A1 | Inhibitors of Protein Tyrosine Phosphatase 1B | WYETH (US) | 2009-02-19 | — | — | US | disclosed |
| US-20050203081-A1 | Inhibitors of protein tyrosine phosphatase 1B | WYETH | 2005-09-15 | — | — | US | disclosed |
| WO-2005081960-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B | WYETH (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203081-A1 | Inhibitors of protein tyrosine phosphatase 1B | PTPRS, PTPRO, PTPRM | OPRK1 4754/4885CYP2C19 2677/4885MAPT 3303/4885 |
| US-20100144730-A1 | PYRIDINONYL PDK1 INHIBITORS | PDK1, PDK2, PDK3 | OPRK1 4386/4885CYP2C19 3922/4885MAPT 3341/4885 |
| US-20090048286-A1 | Inhibitors of Protein Tyrosine Phosphatase 1B | PTPRS, PTPRO, PTPRM | OPRK1 4754/4885CYP2C19 2677/4885MAPT 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.